Literature DB >> 21161315

A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib.

Kazuyuki Numakura1, Norihiko Tsuchiya, Takeshi Yuasa, Mitsuru Saito, Takashi Obara, Hiroshi Tsuruta, Shintaro Narita, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi.   

Abstract

We report a case of Xp11.2 translocation renal cell carcinoma (RCC) whose lung metastases were effectively treated with sunitinib. A 43-year-old woman presenting with upper abdominal pain was diagnosed with a left renal tumor. Laparoscopic left radical nephrectomy was performed. Histopathological examination of the surgical specimen revealed a clear-cell carcinoma of the left kidney. Two years later, multiple lung metastases were detected and the patient was treated daily with 50 mg sunitinib. A computed tomography scan performed after 2 cycles of sunitinib treatment revealed partial regression of these metastases. The partial regression has been maintained for >3 years. In retrospective evaluation of the primary RCC, tumor cells showed strong nuclear staining for transcription factor E3 (TFE3) protein and TFE3 split-fluorescence in-situ hybridization revealed translocation involving the TFE3 gene. These findings strongly support diagnosis of Xp11.2 translocation RCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21161315     DOI: 10.1007/s10147-010-0154-6

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  13 in total

1.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.

Authors:  P Argani; C R Antonescu; P B Illei; M Y Lui; C F Timmons; R Newbury; V E Reuter; A J Garvin; A R Perez-Atayde; J A Fletcher; J B Beckwith; J A Bridge; M Ladanyi
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

2.  Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells.

Authors:  M Ivan; J A Bond; M Prat; P M Comoglio; D Wynford-Thomas
Journal:  Oncogene       Date:  1997-05-22       Impact factor: 9.867

3.  Dual-color, break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma.

Authors:  Minghao Zhong; Patricia De Angelo; Lisa Osborne; Megan Keane-Tarchichi; Michael Goldfischer; Lisa Edelmann; Youfeng Yang; W Marston Linehan; Maria J Merino; Seena Aisner; Meera Hameed
Journal:  Am J Surg Pathol       Date:  2010-06       Impact factor: 6.394

4.  Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

Authors:  G G Malouf; P Camparo; S Oudard; G Schleiermacher; C Theodore; A Rustine; J Dutcher; B Billemont; O Rixe; E Bompas; A Guillot; L Boccon-Gibod; J Couturier; V Molinié; B Escudier
Journal:  Ann Oncol       Date:  2010-02-12       Impact factor: 32.976

Review 5.  Sunitinib: from rational design to clinical efficacy.

Authors:  Laura Q M Chow; S Gail Eckhardt
Journal:  J Clin Oncol       Date:  2007-03-01       Impact factor: 44.544

6.  SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

Authors:  Anne-Marie O'Farrell; Tinya J Abrams; Helene A Yuen; Theresa J Ngai; Sharianne G Louie; Kevin W H Yee; Lily M Wong; Weiru Hong; Leslie B Lee; Ajia Town; Beverly D Smolich; William C Manning; Lesley J Murray; Michael C Heinrich; Julie M Cherrington
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

7.  Pediatric renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.

Authors:  Ni Wayan Winarti; Pedram Argani; Angelo M De Marzo; Jessica Hicks; Ketut Mulyadi
Journal:  Int J Surg Pathol       Date:  2008-01       Impact factor: 1.271

8.  Response to sunitinib malate in advanced alveolar soft part sarcoma.

Authors:  Silvia Stacchiotti; Elena Tamborini; Andrea Marrari; Silvia Brich; Sara Arisi Rota; Marta Orsenigo; Flavio Crippa; Carlo Morosi; Alessandro Gronchi; Marco A Pierotti; Paolo G Casali; Silvana Pilotti
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

9.  TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition.

Authors:  Masumi Tsuda; Ian J Davis; Pedram Argani; Neerav Shukla; Gael G McGill; Makoto Nagai; Tsuyoshi Saito; Marick Laé; David E Fisher; Marc Ladanyi
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

10.  A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib.

Authors:  Toni K Choueiri; Juan-Miguel Mosquera; Michelle S Hirsch
Journal:  Clin Genitourin Cancer       Date:  2009-10       Impact factor: 2.872

View more
  6 in total

1.  Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.

Authors:  James I Geller; Peter F Ehrlich; Nicholas G Cost; Geetika Khanna; Elizabeth A Mullen; Eric J Gratias; Arlene Naranjo; Jeffrey S Dome; Elizabeth J Perlman
Journal:  Cancer       Date:  2015-04-06       Impact factor: 6.860

Review 2.  Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

Authors:  Laurence Albiges; Vincent Molinie; Bernard Escudier
Journal:  Oncologist       Date:  2012-07-17

Review 3.  Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features.

Authors:  Kanishka Sircar; Priya Rao; Eric Jonasch; Federico A Monzon; Pheroze Tamboli
Journal:  Chin J Cancer       Date:  2012-12-07

Review 4.  Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.

Authors:  Xiangming Cheng; Weidong Gan; Gutian Zhang; Xiaogong Li; Hongqian Guo
Journal:  BMC Urol       Date:  2016-07-11       Impact factor: 2.264

5.  PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.

Authors:  Kun Chang; Yuanyuan Qu; Bo Dai; Jian-Yuan Zhao; Hualei Gan; Guohai Shi; Yiping Zhu; Yijun Shen; Yao Zhu; Hailiang Zhang; Dingwei Ye
Journal:  Sci Rep       Date:  2017-05-18       Impact factor: 4.379

6.  MiT translocation renal cell carcinomas: two subgroups of tumours with translocations involving 6p21 [t (6; 11)] and Xp11.2 [t (X;1 or X or 17)].

Authors:  Milan Hora; Tomáš Urge; Ivan Trávníček; Jiří Ferda; Zdeněk Chudáček; Tomáš Vaněček; Michal Michal; Fredrik Petersson; Naoto Kuroda; Ondřej Hes
Journal:  Springerplus       Date:  2014-05-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.